MA44546B1 - Virus adéno-associés variants et procédés d'utilisation - Google Patents

Virus adéno-associés variants et procédés d'utilisation

Info

Publication number
MA44546B1
MA44546B1 MA44546A MA44546A MA44546B1 MA 44546 B1 MA44546 B1 MA 44546B1 MA 44546 A MA44546 A MA 44546A MA 44546 A MA44546 A MA 44546A MA 44546 B1 MA44546 B1 MA 44546B1
Authority
MA
Morocco
Prior art keywords
methods
associated viruses
variant adeno
adeno
variant
Prior art date
Application number
MA44546A
Other languages
English (en)
Other versions
MA44546A1 (fr
Inventor
Loren Looger
Adam Hantman
Dougal Gowanlock Robinson Tervo
Joshua Dudman
Kimberly Ritola
Sarada Viswanathan
Alla Karpova
Bum-Yeol Hwang
David Schaffer
Original Assignee
Univ California
Hughes Howard Med Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Hughes Howard Med Inst filed Critical Univ California
Publication of MA44546A1 publication Critical patent/MA44546A1/fr
Publication of MA44546B1 publication Critical patent/MA44546B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6027—Vectors comprising as targeting moiety peptide derived from defined protein from viruses ssDNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

La présente invention concerne des variantes d'aav qui présentent une préférence pour un mouvement rétrograde dans les neurones et des procédés d'utilisation de telles variantes.
MA44546A 2016-06-15 2017-06-14 Virus adéno-associés variants et procédés d'utilisation MA44546B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662350361P 2016-06-15 2016-06-15
US201662404585P 2016-10-05 2016-10-05
PCT/US2017/037781 WO2017218842A1 (fr) 2016-06-15 2017-06-15 Virus adéno-associés variants et procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA44546A1 MA44546A1 (fr) 2019-07-31
MA44546B1 true MA44546B1 (fr) 2021-03-31

Family

ID=59258370

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44546A MA44546B1 (fr) 2016-06-15 2017-06-14 Virus adéno-associés variants et procédés d'utilisation

Country Status (28)

Country Link
US (2) US10961282B2 (fr)
EP (2) EP3472183B1 (fr)
JP (2) JP7094277B2 (fr)
KR (2) KR102522661B1 (fr)
CN (2) CN116003532A (fr)
AU (2) AU2017286652B2 (fr)
BR (1) BR112018076090A2 (fr)
CA (1) CA3028113A1 (fr)
DK (1) DK3472183T5 (fr)
EA (1) EA201990033A1 (fr)
ES (1) ES2962611T3 (fr)
FI (1) FI3472183T3 (fr)
HR (1) HRP20231403T1 (fr)
HU (1) HUE063755T2 (fr)
IL (2) IL263719B2 (fr)
LT (1) LT3472183T (fr)
MA (1) MA44546B1 (fr)
MX (2) MX2018015770A (fr)
MY (1) MY190221A (fr)
PH (1) PH12018502664A1 (fr)
PL (1) PL3472183T3 (fr)
PT (1) PT3472183T (fr)
RS (1) RS64769B1 (fr)
SG (1) SG11201811189RA (fr)
SI (1) SI3472183T1 (fr)
SM (1) SMT202300372T1 (fr)
WO (1) WO2017218842A1 (fr)
ZA (1) ZA201900278B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4005603T3 (da) * 2011-04-22 2024-11-25 Univ California Adeno-associerede virus-virioner med variant kapsid og fremgangsmåder til anvendelse heraf
CA2907799A1 (fr) 2013-05-31 2014-12-04 The Regents Of The University Of California Variants de virus adeno-associes et leurs methodes d'utilisation
CN116333057A (zh) * 2016-05-13 2023-06-27 4D分子治疗有限公司 腺相关病毒变体衣壳和其使用方法
MA44546B1 (fr) * 2016-06-15 2021-03-31 Univ California Virus adéno-associés variants et procédés d'utilisation
CA3029833A1 (fr) 2016-07-29 2018-02-01 The Regents Of The University Of California Virions de virus adeno-associe a variant de capside et methodes d'utilisation associees
BR112019019015A2 (pt) 2017-06-30 2020-04-14 Univ California vírions de vírus adeno-associado com capsídeos variantes e seus métodos de uso
EP3676373A4 (fr) 2017-08-28 2021-06-09 The Regents of The University of California Variants de capside de virus adéno-associé et leurs procédés d'utilisation
EP3697896A1 (fr) * 2017-10-16 2020-08-26 Vigeneron GmbH Vecteurs aav
EA202190358A1 (ru) * 2018-07-31 2021-05-04 Корнелл Юниверсити Способы генной терапии для контроля функции органов
CN113966399A (zh) 2018-09-26 2022-01-21 加州理工学院 用于靶向基因疗法的腺相关病毒组合物
WO2021022208A1 (fr) * 2019-08-01 2021-02-04 Kaplitt Michael G Thérapie génique ciblée pour traiter des maladies neurologiques
WO2022011390A1 (fr) * 2020-07-08 2022-01-13 Baylor College Of Medicine Thérapie génique pour encéphalopathie stxbp1
CN111825772B (zh) * 2020-07-30 2023-10-20 中国科学院精密测量科学与技术创新研究院 具有变异衣壳蛋白的腺相关病毒及其应用
CA3181024A1 (fr) 2020-08-06 2022-02-10 Fundacion Para La Investigacion Medica Aplicada Particules virales a utiliser dans le traitement de tauopathies de type maladie d'alzheimer par therapie genique
AU2021399882A1 (en) * 2020-12-16 2023-07-06 Children's Medical Research Institute Aav capsids and vectors
AU2021401998A1 (en) * 2020-12-16 2023-08-03 Children's Medical Research Institute Adeno-associated virus capsids and vectors
IL309351A (en) 2021-06-17 2024-02-01 Meiragtx Uk Ii Ltd AAV production methods
US20240307559A1 (en) 2021-07-14 2024-09-19 Meiragtx Uk Ii Limited Kcnv2 gene therapy
US20250281639A1 (en) * 2021-07-14 2025-09-11 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treating chronic pain and for retrograde transduction of neurons
KR20240055728A (ko) 2021-07-14 2024-04-29 메이라지티엑스 유케이 Ii 리미티드 Retgc 유전자 요법
EP4448555A2 (fr) 2021-12-15 2024-10-23 Meiragtx UK II Limited Expression polycistronique de peptides intestinaux
EP4499672A1 (fr) * 2022-03-30 2025-02-05 University of Pittsburgh - of the Commonwealth System of Higher Education Vecteurs viraux adéno-associés pour l'administration d'acides nucléiques à des cellules ganglionnaires rétiniennes et/ou des cellules de l'épithélium pigmentaire rétinien
WO2024059667A2 (fr) * 2022-09-13 2024-03-21 Dyno Therapeutics, Inc. Variants de capside et leurs méthodes d'utilisation
AU2023342734A1 (en) 2022-09-16 2025-03-27 King's College London Compositions and methods for treating neurological diseases
EP4601709A1 (fr) 2022-10-11 2025-08-20 MeiraGTx UK II Limited Constructions d'expression d'upf1
KR20250102134A (ko) 2022-10-11 2025-07-04 메이라지티엑스 유케이 Ii 리미티드 Atp7b 유전자 요법
JP2025535118A (ja) 2022-10-11 2025-10-22 メイラグティーエックス ユーケー アイアイ リミティド Ａａｖカプシドの精製のためのクロマトグラフィー方法
CN120265310A (zh) 2022-10-11 2025-07-04 梅里特斯英国第二有限公司 Aav基因疗法的配制品
EP4601612A2 (fr) 2022-10-11 2025-08-20 MeiraGTx UK II Limited Éléments régulateurs d'acide nucléique aux fins de l'expression génique dans le muscle et procédés d'utilisation
WO2024126696A1 (fr) 2022-12-14 2024-06-20 King's College London Compositions et méthodes de traitement de maladies neurologiques
JP2026501737A (ja) * 2023-01-05 2026-01-16 エミュジェン セラピューティクス エルエルシー レトロ－ａａｖ、および神経変性疾患の処置における使用
IL321780A (en) * 2023-01-05 2025-08-01 Emugen Therapeutics Llc Neural promoters and their uses
WO2024161022A2 (fr) 2023-02-03 2024-08-08 King's College London Compositions et méthodes de traitement de maladies neurologiques
KR20260013513A (ko) 2023-04-13 2026-01-28 메이라지티엑스 진 레귤레이션 리미티드 염증 유도성 프로모터
EP4698153A1 (fr) * 2023-04-18 2026-02-25 University of Massachusetts Variants de capside et utilisations associées
WO2024252182A1 (fr) 2023-06-08 2024-12-12 Meiragtx Uk Ii Limited Chromatographie par échange de cations pour capture de vaa
WO2025126153A2 (fr) 2023-12-14 2025-06-19 Aviadobio Ltd. Compositions et méthodes de traitement de maladies neurologiques à médiation par sod1

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US9233131B2 (en) * 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
WO2006119150A2 (fr) * 2005-04-29 2006-11-09 Beth Israel Deaconess Medical Center Compositions et methode de ciblage de vecteurs viraux
US20090215879A1 (en) 2008-02-26 2009-08-27 University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
EP2396343B1 (fr) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Vecteurs viraux modifiés et procédés de fabrication et d'utilisation de ceux-ci
DK4005603T3 (da) * 2011-04-22 2024-11-25 Univ California Adeno-associerede virus-virioner med variant kapsid og fremgangsmåder til anvendelse heraf
US9719992B2 (en) 2011-10-07 2017-08-01 Howard Hughes Medical Institute Genetically encoded biosensors
WO2013174760A1 (fr) * 2012-05-25 2013-11-28 Deutsches Krebsforschungszentrum Vecteurs aav optimisés pour des taux de transduction élevés dans des cellules dendritiques
US9518980B2 (en) 2012-10-10 2016-12-13 Howard Hughes Medical Institute Genetically encoded calcium indicators
US9518996B2 (en) 2013-08-05 2016-12-13 Howard Hughes Medical Institute Fluorescent protein-based calcium integrators
US9585971B2 (en) * 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
CN104592364B (zh) * 2013-10-30 2018-05-01 北京大学 定点突变和定点修饰的腺相关病毒、其制备方法及应用
GB201403684D0 (en) * 2014-03-03 2014-04-16 King S College London Vector
WO2015164757A1 (fr) * 2014-04-25 2015-10-29 Oregon Health & Science University Procedes de cartographie d'epitopes d'anticorps de neutralisation virale
WO2016054554A1 (fr) * 2014-10-03 2016-04-07 University Of Massachusetts Virus adéno-associés greffés au moyen de peptides de ciblage hétérologues
BR112017010447A2 (pt) * 2014-11-21 2018-05-15 The University Of North Carolina At Chapel Hill vetores de aav direcionados ao sistema nervoso central
US9644007B2 (en) 2014-12-23 2017-05-09 Howard Hughes Medical Institute Red genetically encoded calcium indicators and methods of use
CN116333057A (zh) * 2016-05-13 2023-06-27 4D分子治疗有限公司 腺相关病毒变体衣壳和其使用方法
MA44546B1 (fr) * 2016-06-15 2021-03-31 Univ California Virus adéno-associés variants et procédés d'utilisation
CA3029833A1 (fr) * 2016-07-29 2018-02-01 The Regents Of The University Of California Virions de virus adeno-associe a variant de capside et methodes d'utilisation associees

Also Published As

Publication number Publication date
PH12018502664A1 (en) 2019-10-07
AU2021225247B2 (en) 2023-02-16
JP7094277B2 (ja) 2022-07-01
RS64769B1 (sr) 2023-11-30
LT3472183T (lt) 2023-09-25
US20190300579A1 (en) 2019-10-03
KR102800951B1 (ko) 2025-04-25
CA3028113A1 (fr) 2017-12-21
PL3472183T3 (pl) 2024-02-12
AU2017286652B2 (en) 2021-10-07
IL263719B1 (en) 2023-05-01
KR20230054754A (ko) 2023-04-25
CN116003532A (zh) 2023-04-25
HRP20231403T1 (hr) 2024-02-16
SMT202300372T1 (it) 2023-11-13
KR102522661B1 (ko) 2023-04-18
AU2021225247A1 (en) 2021-09-30
DK3472183T5 (da) 2024-09-09
US20210230231A1 (en) 2021-07-29
MX2018015770A (es) 2019-08-29
EP3472183A1 (fr) 2019-04-24
MY190221A (en) 2022-04-06
JP2022126759A (ja) 2022-08-30
HUE063755T2 (hu) 2024-01-28
EP4268852A3 (fr) 2024-02-07
EP4268852A2 (fr) 2023-11-01
MX2024000505A (es) 2024-03-19
BR112018076090A2 (pt) 2019-03-26
ES2962611T3 (es) 2024-03-20
CN109641939B (zh) 2022-11-08
US11939355B2 (en) 2024-03-26
IL263719A (en) 2019-01-31
DK3472183T3 (da) 2023-11-06
SI3472183T1 (sl) 2023-11-30
EA201990033A1 (ru) 2019-06-28
PT3472183T (pt) 2023-11-16
CN109641939A (zh) 2019-04-16
MA44546A1 (fr) 2019-07-31
EP3472183B1 (fr) 2023-08-09
JP7579301B2 (ja) 2024-11-07
JP2019518793A (ja) 2019-07-04
IL263719B2 (en) 2023-09-01
IL300981A (en) 2023-04-01
AU2017286652A1 (en) 2019-01-24
FI3472183T3 (fi) 2023-11-03
ZA201900278B (en) 2022-04-28
KR20190039930A (ko) 2019-04-16
SG11201811189RA (en) 2019-01-30
US10961282B2 (en) 2021-03-30
WO2017218842A1 (fr) 2017-12-21

Similar Documents

Publication Publication Date Title
MA44546B1 (fr) Virus adéno-associés variants et procédés d'utilisation
IL286911A (en) Recombinant adeno-associated viruses and their uses
IL281930A (en) Rna particles comprising polysarcosin
EP4061427A4 (fr) Variants de vecteurs viraux adéno-associés
MA43982A (fr) Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1
PH12018502673A1 (en) Anti-zika virus antibodies and methods of use
EP3841109A4 (fr) Compositions et procédés pour moduler l'efficacité de transduction de virus adéno-associés
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
EP3953478A4 (fr) Procédés et compositions pour améliorer l'assemblage de virus adéno-associés (aav)
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
EP3857127A4 (fr) Dispositif d'allumage à l'épreuve des enfants
EA201791754A1 (ru) АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
ZA201807595B (en) Protoporphyrinogen oxidase variants and methods and compositions for conferring and/or enhancing herbicide tolerance using the same
EP3603350A4 (fr) Procédés à plasma énergétiquement efficaces pour générer des charges libres, de l'ozone et de la lumière
EP3403675A4 (fr) Virion viral adéno-associé pour son utilisation dans le traitement de l'épilepsie
EP3403673A4 (fr) Composition pour empêcher ou améliorer la chute et le grisonnement des cheveux, et utilisation de cette dernière
EP3898445A4 (fr) Récipient à l'épreuve des enfants
ZA202104244B (en) Recombinant viruses and the uses thereof
FR3072973B1 (fr) Particules pseudo-virales utiles pour traiter des dysfonctionnements immunitaires
EP3467593A4 (fr) Ensemble de réception de force d'entraînement et boîte de traitement utilisant l'ensemble
EP3503928A4 (fr) Méthodes et compositions pour le traitement d'états canins au moyen d'un virus adéno-associé recombinant auto-complémentaire.
EP3458038A4 (fr) Transporteurs d'oxygène réduit et leur utilisation destinés au traitement de la carboxyhémoglobinémie
EP3339439A4 (fr) Anticorps monoclonal neutralisant l'infectiosité de tous les virus ebola
EP3580275A4 (fr) Polypropylènes à haute résistance à l'état fondu présentant une aptitude au traitement améliorée